Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

Brain Research Reviews

Volumn 48, Issue 2, 2005, Pages 379-387

  Mandel, Silvia ^b   Weinreb, Orly ^b   Amit, Tamar ^b   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NONE

Author keywords

Bcl 2; Cell death; Ladostigil; MAPK; Neuroprotection; Parkinson's disease; PKC; Propargylamine; Rasagiline

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMPHETAMINE; AMYLOID PRECURSOR PROTEIN; FAS ANTIGEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GLUTAMIC ACID; LADOSTIGIL; LINSIDOMINE; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NCX 2057; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; PLACEBO; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; RASAGILINE; SALSOLINOL; TV 1022; UO 126;

ANOXIA; APOPTOSIS; CELL DEATH; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHELATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HEAD INJURY; HUMAN; IN VIVO STUDY; ISCHEMIA; MITOCHONDRION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 17844406615     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2004.12.027     Document Type: Conference Paper

References (80)

1. A. Aderem The MARCKS brothers: a family of protein kinase C substrates Cell 71 1992 713 716
2. Y. Akao, W. Maruyama, H. Yi, M. Shamoto-Nagai, M.B.H. Youdim, and M. Naoi An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells Neurosci. Lett. 326 2002 105 108
3. O. Bar-Am, T. Amit, and M.B.H. Y. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline Neurosci. Lett. 355 2004 169 172
4. O. Bar-Am, M. Yogev-Falach, T. Amit, Y. Sagi, and M.B.H. Youdim Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo J. Neurochem. 89 2004 1119 1125
5. F. Battaini, A. Pascale, R. Paoletti, and S. Govoni The role of anchoring protein RACK1 in PKC activation in the ageing rat brain Trends Neurosci. 20 1997 410 415
6. F. Battaini, A. Pascale, L. Lucchi, G.M. Pasinetti, and S. Govoni Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients Exp. Neurol. 159 1999 559 564
7. L. Benussi, S. Govoni, L. Gasparini, G. Binetti, M. Trabucchi, A. Bianchetti, and M. Racchi Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts Neurosci. Lett. 240 1998 97 101
8. P.J. Blackshear The MARCKS family of cellular protein kinase C substrates J. Biol. Chem. 268 1993 1501 1504
9. J.D. Buxbaum, S.E. Gandy, P. Cicchetti, M.E. Ehrlich, A.J. Czernik, R.P. Fracasso, T.V. Ramabhadran, A.J. Unterbeck, and P. Greengard Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation Proc. Natl. Acad. Sci. U. S. A. 87 1990 6003 6006
10. A. Caputi, S. Barindelli, L. Pastorino, M. Cimino, J.D. Buxbaum, F. Cattabeni, and M. Di Luca Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C J. Neurochem. 68 1997 2523 2529
11. D.S. Cassarino, and J.P. Bennett Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration Brain Res., Brain Res. Rev. 29 1999 1 25
12. M.R. Farlow Update on rivastigmine Neurologist 9 2003 230 234
13. J.P. Finberg, T. Takeshima, J.M. Johnston, and J.W. Commissiong Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor NeuroReport 9 1998 703 707
14. R. Furlan, A. Kurne, A. Bergami, E. Brambilla, R. Maucci, L. Gasparini, E. Butti, G. Comi, E. Ongini, and G. Martino A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis J. Neuroimmunol. 150 2004 10 19
15. L.N. Grinberg, H. Newmark, N. Kitrossky, E. Rahamim, M. Chevion, and E.A. Rachmilewitz Protective effects of tea polyphenols against oxidative damage to red blood cells Biochem. Pharmacol. 54 1997 973 978
16. E. Grunblatt, S. Hoyer, and P. Riederer Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease J. Neural Transm. 111 2004 367 386
17. W. Gsell, N. Reichert, M.B.H. Youdim, and P. Riederer Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study J. Neural Transm., Suppl. 45 1995 271 279
18. Q. Guo, B. Zhao, M. Li, S. Shen, and W. Xin Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes Biochim. Biophys. Acta 1304 1996 210 222
19. T. Hama, K.P. Huang, and G. Guroff Protein kinase C as a component of a nerve growth factor-sensitive phosphorylation system in PC12 cells Proc. Natl. Acad. Sci. U. S. A. 83 1986 2353 2357
20. W. Huang, Y. Chen, E. Shohami, and M. Weinstock Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse Eur. J. Pharmacol. 366 1999 127 135
21. K.A. Jellinger Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J. Neural Transm., Suppl. 1991 1 29
22. L.W. Jin, and T. Saitoh Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy Drugs Aging 6 1995 136 149
23. T. Kimura, H. Yamamoto, J. Takamatsu, T. Yuzuriha, E. Miyamoto, and T. Miyakawa Phosphorylation of MARCKS in Alzheimer disease brains NeuroReport 11 2000 869 873
24. T. Kinouchi, H. Sorimachi, K. Maruyama, K. Mizuno, S. Ohno, S. Ishiura, and K. Suzuki Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts FEBS Lett. 364 1995 203 206
25. A. Kribben, E.D. Wieder, X. Li, V. van Putten, Y. Granot, R.W. Schrier, and R.A. Nemenoff AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C Am. J. Physiol. 265 1993 C939 C945
26. M. Kumamoto, T. Sonda, K. Nagayama, and M. Tabata Effects of pH and metal ions on antioxidative activities of catechins Biosci. Biotechnol. Biochem. 65 2001 126 132
27. Y. Levites, O. Weinreb, G. Maor, M.B.H. Youdim, and S. Mandel Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration J. Neurochem. 78 2001 1073 1082
28. Y. Levites, T. Amit, M.B.H. Youdim, and S. Mandel Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action J. Biol. Chem. 277 2002 30574 30580
29. L. Lin, B. Georgievska, A. Mattsson, and O. Isacson Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation Proc. Natl. Acad. Sci. U. S. A. 96 1999 12108 12113
30. P. Maher How protein kinase C activation protects nerve cells from oxidative stress-induced cell death J. Neurosci. 21 2001 2929 2938
31. S. Mandel, O. Weinreb, and M.B.H. Youdim Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs Trends Pharmacol. Sci. 24 2003 184 191
32. W. Maruyama, Y. Akao, M.B.H. Youdim, and M. Naoi Neurotoxins induce apoptosis in dopamine neurons: protection by N- propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022 J. Neural Transm., Suppl. 2000 171 186
33. W. Maruyama, M.B.H. Youdim, and M. Naoi Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagiline and TV1022 Ann. N. Y. Acad. Sci. 939 2000 320 329
34. W. Maruyama, Y. Akao, M.B.H. Youdim, A.A. Boulton, B.A. Davis, and M. Naoi Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol J. Neurochem. 78 2001 727 735
35. W. Maruyama, A.A. Boulton, B.A. Davis, P. Dostert, and M. Naoi Enantio-specific induction of apoptosis by an endogenous neurotoxin, N- methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine J. Neural Transm. 108 2001 11 24
36. E. Masliah, G.M. Cole, L.A. Hansen, M. Mallory, T. Albright, R.D. Terry, and T. Saitoh Protein kinase C alteration is an early biochemical marker in Alzheimer's disease J. Neurosci. 11 1991 2759 2767
37. H. Matsushima, S. Shimohama, M. Chachin, T. Taniguchi, and J. Kimura Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease J. Neurochem. 67 1996 317 323
38. R.K. McNamara, and R.H. Lenox Distribution of the protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain J. Neurol. 397 1998 337 356
39. R.K. McNamara, D.J. Stumpo, L.M. Morel, M.H. Lewis, E.K. Wakeland, P.J. Blackshear, and R.H. Lenox Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background Proc. Natl. Acad. Sci. U. S. A. 95 1998 14517 14522
40. J. Mills, and P.B. Reiner Regulation of amyloid precursor protein cleavage J. Neurochem. 72 1999 443 460
41. D. Mochly-Rosen Localization of protein kinases by anchoring proteins: a theme in signal transduction Science 268 1995 247 251
42. H.P. Montz, G.E. Davis, S.D. Skaper, M. Manthorpe, and S. Varon Tumor-promoting phorbol diester mimics two distinct neuronotrophic factors Brain Res. 355 1985 150 154
43. E.M. Mutisya, A.C. Bowling, and M.F. Beal Cortical cytochrome oxidase activity is reduced in Alzheimer's disease J. Neurochem. 63 1994 2179 2184
44. M. Naoi, and W. Maruyama Future of neuroprotection in Parkinson's disease Parkinsonism Relat. Disord. 8 2001 139 145
45. Y. Nishizuka The molecular heterogeneity of protein kinase C and its implications for cellular regulation Nature 334 1988 661 665
46. R.M. Nitsch, B.E. Slack, R.J. Wurtman, and J.H. Growdon Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors Science 258 1992 304 307
47. W.D. Parker Jr., C.A. Oley, and J.K. Parks A defect in mitochondrial electron-transport activity (NADH-coenzyme Q oxidoreductase) in Leber's hereditary optic neuropathy N. Engl. J. Med. 320 1989 1331 1333
48. R. Rafique, A.H. Schapira, and J.M. Coper Mitochondrial respiratory chain dysfunction in ageing; influence of vitamin E deficiency Free Radic. Res. 38 2004 157 165
49. J.T. Rogers, and D.K. Lahiri Metal and inflammatory targets for Alzheimer's disease Curr. Drug Targets 5 2004 535 551
50. S. Rossner, U. Ueberham, J. Yu, L. Kirazov, R. Schliebs, J.R. Perez-Polo, and V. Bigl In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity Eur. J. Neurosci. 9 1997 2125 2134
51. G.S. Roth, J.A. Joseph, and R.P. Mason Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging Trends Neurosci. 18 1995 203 206
52. P.P. Ruvolo, X. Deng, B.K. Carr, and W.S. May A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis J. Biol. Chem. 273 1998 25436 25442
53. Y. Sagi, M. Weinstock, and M.B.H. Youdim Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor J. Neurochem. 2 2003 290 297
54. T. Saitoh, K. Horsburgh, and E. Masliah Hyperactivation of signal transduction systems in Alzheimer's disease Ann. N. Y. Acad. Sci. 695 1993 34 41
55. J. Saura, J.M. Luque, A.M. Cesura, M. Da Prada, V. Chan-Palay, G. Huber, J. Loffler, and J.G. Richards Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography Neuroscience 62 1994 15 30
56. S. Shimohama, M. Narita, H. Matsushima, J. Kimura, M. Kameyama, M. Hagiwara, H. Hidaka, and T. Taniguchi Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease Neurology 43 1993 1407 1413
57. B.E. Slack, R.M. Nitsch, E. Livneh, G.M. Kunz Jr., J. Breu, H. Eldar, and R.J. Wurtman Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha J. Biol. Chem. 268 1993 21097 21101
58. J. Sterling, Y. Herzig, T. Goren, N. Finkelstein, D. Lerner, W. Goldenberg, I. Miskolczi, S. Molnar, F. Rantal, T. Tamas, G. Toth, A. Zagyva, A. Zekany, G. Lavian, A. Gross, R. Friedman, M. Razin, W. Huang, B. Krais, M. Chorev, M.B.H. Youdim, and M. Weinstock Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 45 2002 5260 5279
59. The Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease Arch. Neurol. 59 2002 1937 1993
60. The Parkinson Study Group A control randomized delayed start study of rasagiline in early Parkinson's disease Arch. Neurol. 61 2004 561 566
61. Y. Tsujimoto, and S. Shimizu Bcl-2 family: life-or-death switch FEBS Lett. 466 2000 6 10
62. M.R. Vianna, D.M. Barros, T. Silva, H. Choi, C. Madche, C. Rodrigues, J.H. Medina, and I. Izquierdo Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats Psychopharmacology (Berl) 150 2000 77 84
63. H.Y. Wang, M.R. Pisano, and E. Friedman Attenuated protein kinase C activity and translocation in Alzheimer's disease brain Neurobiol. Aging 15 1994 293 298
64. O. Weinreb, O. Bar-Am, T. Amit, O. Chillag-Talmor, and M.B.H. Youdim Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members FASEB J. 2004 (04-1916fje)
65. M. Weinstock, C. Bejar, R.H. Wang, T. Poltyrev, A. Gross, J. Finberg, and M.B.H. Youdim TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease J. Neural Transm. Suppl. 60 2000 S157 S170
66. M. Weinstock, N. Kirschbaum-Slager, P. Lazarovici, C. Bejar, M.B.H. Youdim, and S. Shoham Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs Ann. N. Y. Acad. Sci. 939 2001 148 161
67. M. Weinstock, T. Poltyrev, C. Bejar, and M.B. Youdim Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression Psychopharmacology (Berl) 160 2002 318 324
68. M. Weinstock, E. Gorodetskya, T. Poltyrev, A. Gross, Y. Sagi, and M.B.H. Youdim A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease Neuropsychopharmacol. Biol. Psychiatry 27 2003 556 561
69. G.L. Wenk, K. McGann-Gramling, B. Hauss-Wegrzyniak, D. Ronchetti, R. Maucci, S. Rosi, L. Gasparini, and E. Ongini Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid J. Neurochem. 89 2004 484 493
70. S.W. Yeon, M.W. Jung, M.J. Ha, S.U. Kim, K. Huh, M.J. Savage, E. Masliah, and I. Mook-Jung Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein Biochem. Biophys. Res. Commun. 280 2001 782 787
71. M. Yogev-Falach, T. Amit, O. Bar-Am, Y. Sagi, M. Weinstock, and M.B.H. Youdim The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline FASEB J. 16 2002 1674 1676
72. M. Yogev-Falach, T. Amit, O. Bar-AM, and M.B.H. Youdim The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing FASEB J. 17 2003 2325 2327
73. M.B.H. Youdim Rasagiline: an anti-Parkinson drug with neuroprotective activity Expert Rev. Neurotherapeutics 3 2003 737 749
74. M.B.H. Youdim, and M. Weinstock Molecular basis of neuroprotective activities of rasagiline and the anti Alzheimer drug, TV3326, [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] Cell. Mol. Neurobiol. 21 2002 555 573
75. M.B.H. Youdim, A. Gross, and J.P.M. Finberg Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B Br. J. Pharmacol. 132 2001 500 506
76. M.B.H. Youdim, A. Wadia, N.A. Tatton, and M. Weinstock The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo Ann. N. Y. Acad. Sci. 939 2001 450 458
77. M.B.H. Youdim, T. Amit, M. Yogev-Falach, O. Bar-Am, W. Maruyama, and M. Naoi The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline Biochem. Pharmacol. 66 2003 1635 1641
78. M.B.H. Youdim, M. Fridkin, and H. Zheng Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases J. Neural Transm. 2004 1 16
79. M.B.H. Youdim, G. Stephenson, and D. Ben Shachar Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Ann. N. Y. Acad. Sci. 1012 2004 306 325
80. L. Zecca, M.B.H. Youdim, P. Riederer, J.R. Connor, and R.R. Crichton Iron, brain ageing and neurodegenerative disorders Nat. Rev. Neurosci. 5 2004 863 868